MBX Biosciences, Inc. (MBX)
| Market Cap | 2.97B +485.2% |
| Revenue (ttm) | n/a |
| Net Income | -104.29M |
| EPS | -2.41 |
| Shares Out | 48.16M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 518,585 |
| Open | 62.25 |
| Previous Close | 63.00 |
| Day's Range | 59.47 - 63.04 |
| 52-Week Range | 9.63 - 72.64 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 88.36 (+43.44%) |
| Earnings Date | Aug 6, 2026 |
About MBX
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy fo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for MBX stock is "Strong Buy." The 12-month stock price target is $88.36, which is an increase of 43.44% from the latest price.
News
MBX Biosciences doses first patient in oPTimize clinical trial
MBX Biosciences (MBX) announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidis...
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism
Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit
MBX Biosciences reinstated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye reinstated coverage of MBX Biosciences (MBX) with an Overweight rating and $88 price target The firm sees an attractive setup for MBX citing its “intriguing” obesity…
MBX Biosciences price target raised to $88 from $70 at Truist
Truist raised the firm’s price target on MBX Biosciences (MBX) to $88 from $70 and keeps a Buy rating on the shares as part of a broader research note updating…
MBX Biosciences price target raised to $88 from $70 at Barclays
Barclays raised the firm’s price target on MBX Biosciences (MBX) to $88 from $70 and keeps an Overweight rating on the shares. The firm updated the company’s model post the…
MBX Biosciences reports Q2 EPS (78c), consensus (59c)
“The second quarter was highlighted by important milestones across our pipeline, including a first look at clinical data for MBX 4291 supporting its potential for true once-monthly dosing in obesity,”...
MBX Biosciences Earnings release: Q2 2026
MBX Biosciences released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
MBX Biosciences Quarterly report: Q2 2026
MBX Biosciences has published its Q2 2026 quarterly earnings report on August 6, 2026.
MBX Biosciences Slides: Corporate presentation
MBX Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
MBX Biosciences price target raised to $91 from $57 at Mizuho
Mizuho raised the firm’s price target on MBX Biosciences (MBX) to $91 from $57 and keeps an Outperform rating on the shares. The firm updated the company’s model to incorporate…
MBX Biosciences price target raised to $90 from $60 at UBS
UBS analyst Michael Yee raised the firm’s price target on MBX Biosciences (MBX) to $90 from $60 and keeps a Buy rating on the shares. The firm remains bullish on…
MBX Biosciences CEO Kent Hawryluk steps down, Steve Hoerter succeeds
MBX Biosciences (MBX) announced that its board of directors has appointed Steve Hoerter, current executive chairman of the board, as its new chairman and CEO. Hoerter succeeds Kent Hawryluk, who…
MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth
CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci...
MBX Biosciences down 19% at $30.05 after announcing canvuparatide study results
08:19 EDT MBX Biosciences (MBX) down 19% at $30.05 after announcing canvuparatide study results
MBX Biosciences Transcript: Study result
Once-weekly canvuparatide demonstrated sustained efficacy and safety over one year in chronic hypoparathyroidism, maintaining normal serum calcium, reducing urinary calcium, and restoring bone turnover. High patient retention and positive trends in patient-reported outcomes support its potential as a best-in-class PTH replacement, with Phase III trials set to begin soon.
MBX Biosciences Slides: Study result
MBX Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on June 12, 2026.
MBX Biosciences Press release: Study result
MBX Biosciences issued a press release on June 12, 2026, disclosing material business information to investors.
MBX Biosciences announces results from Avail, canvuparatide trials
MBX Biosciences (MBX) announced full results from the 12-week Avail Phase 2 trial and new one-year data from the ongoing open-label extension study of once-weekly canvuparatide in adult patients with…
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial
MBX Biosciences Transcript: AGM 2026
The meeting covered director elections and auditor ratification, with all proposals approved by stockholders. Voting procedures were clearly outlined, and final results will be reported in official filings.
MBX Biosciences Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted a robust clinical pipeline leveraging a validated PEP platform, with key programs in obesity and hypoparathyroidism advancing toward pivotal milestones. Once-weekly and monthly dosing strategies aim to improve patient adherence and tolerability, with upcoming data at ENDO and further obesity results expected in Q4.
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel pre...
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
CARMEL, Ind. and BURLINGTON, Mass.
MBX Biosciences price target raised to $56 from $50 at Stifel
Stifel raised the firm’s price target on MBX Biosciences (MBX) to $56 from $50 and keeps a Buy rating on the shares following the company’s investor day meeting. Published first…
MBX Biosciences price target raised to $70 from $66 at Barclays
Barclays raised the firm’s price target on MBX Biosciences (MBX) to $70 from $66 and keeps an Overweight rating on the shares. The MBX 4291 data in obesity is early…